Cost‑utility analysis of encorafenib plus cetuximab combined with mFOLFOX6 as first‑line therapy for BRAF V600E‑mutant metastatic colorectal cancer
ZHU Tongming, YI Jia, LI Wenqiang, ZHU Xiaowei, SHEN Aizong
Chinese Journal of Hospital Pharmacy . 2026, (6): 683 -690 .  DOI: 10.13286/j.1001-5213.2026.06.11

Information
Governed by: China Association for Science and Technology
Sponsored by: Chinese Pharmaceutical Association
Published by: Editorial Office of Chinese Journal of Hospital Pharmacy
ISSN 1001-5213
CN 42-1204/R
Contact
Website Copyright © Chinese Journal of Hospital Pharmacy, All Rights Reserved.
Tel: 027-82836596
E-mail：pharmacy@vip.163.com
Wechat